Benedict Law, Ph.D.
An urinary drug disposing approach for treatment of bladder Cancer (R01 CA276506)
National Cancer Institute
Benedict Law, Ph.D.
A multiplexed approach to improve tumoral targeting and chemotherapeutic treatment (R01 CA222802)
National Cancer Institute
James Kelly, Ph.D.
The Development of Radiolabeled Positional isomers of [11C]Pyruvate for Imaging Cancer Metabolism (R21 EB029649)
National Institute of Biomedical Imaging & Bioengineering
James Kelly, Ph.D.
Investigating PK modulation in targeted radiotherapy (RT, LLC 224196)
Ratio Therapeutics, LLC
Moonsoo Jin, Ph.D.
CAR T Cells for Advanced Thyroid Cancer (R01 CA254035)
National Cancer Institute
Moustafa Gabr, Ph.D.
Small molecule-mediated inhibition of T cell immunoglobulin and mucin domain 3 (TIM-3) as an immunotherapeutic strategy for Acute Myeloid Leukemia (AML) (DBG-22-120-01-ET)
American Cancer Society
Moustafa Gabr, Ph.D.
First-in-class small molecule LAG-3 inhibitors for non-small lung cancer therapy (EUPF 228153)
Elsa U. Pardee Foundation
Seung Koo Lee, Ph.D.
Instantaneous tumor spray for real-time surgical guidance (R44 CA275434)
National Cancer Institute
Vanessa Bellat, Ph.D.
Customized nanofibers with preferential lung-targeting properties for treating metastatic pulmonary tumors (R37 CA278671)
National Cancer Institute
Sarah M. Cheal, Ph.D.
DOTA-based pre-targeting of alpha emitters (R01 CA233896)
National Cancer Institute
Michelle Bradbury, M.D., Ph.D.
Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer (R01 CA253658)
National Cancer Institute